Koers Ventrus Biosciences Inc Nasdaq
Aandelen
US9228221019
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 73,41 mln. 68,05 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -52 mln. -48,2 mln. | Nettowinst (verlies) 2025 * | -54 mln. -50,06 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,42
x | K/w-verhouding 2025 * |
-1,39
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 66,94% |
Recentste transcriptie over Ventrus Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jason Okazaki
CEO | Chief Executive Officer | 48 | 30-03-20 |
Anuj Gaggar
CTO | Chief Tech/Sci/R&D Officer | 46 | 08/11 |
William Delaney
CTO | Chief Tech/Sci/R&D Officer | 52 | 01-06-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Susan Mahony
BRD | Director/Board Member | 59 | 14-12-17 |
Gina Consylman
BRD | Director/Board Member | 52 | 20-10-20 |
William Ringo
CHM | Chairman | 78 | 01-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,22% | 72,5 mld. | |
+13,69% | 9,11 mld. | |
-11,75% | 5,07 mld. | |
+59,61% | 5,01 mld. | |
+2,62% | 3,85 mld. | |
-17,54% | 2,46 mld. | |
+21,35% | 2,44 mld. | |
-27,82% | 2,26 mld. | |
+25,13% | 2,27 mld. |
- Beurs
- Aandelen
- Koers ASMB
- Koers